rivoceranib,camrelizumab,shr-1210
elevar therapeutics,jiangsu hengrui pharmaceuticals
['hcc', 'rivoceranib', 'camrelizumab']
findings presented at #esmo2022 show the survival benefits of camrelizumab plus rivoceranib in patients with unresectable #hcc. 
Oncology news and insights from leading researchers and cancer centers.